作为T细胞参与者,Tebentafusp促进了巨细胞的重编程,与IL-2结合,克服了巨细胞在癌症中的免疫抑制
Esra Güç1, Agatha Treveil1, Emma Leach1
1Immunocore Ltd, Abingdon-on-Thames, UK.
Nature communications
|March 11, 2025
概括
对于转移性阴膜黑色素瘤 (mUM) 的新疗法Tebentafusp通过重编程巨细胞来增强抗瘤T细胞活性. 将其与IL-2结合使用可能进一步有利于患有高瘤相关巨细胞 (TAM) 的患者.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 癌症研究 癌症研究
背景情况:
- 卵巢黑色素瘤 (UM) 是成年人最常见的眼内癌.
- 转移性UM (mUM) 影响大约一半的患者,治疗选择有限.
- 泰班塔法斯普 (ImmTAC) 改善了HLA-A*02:01+mUM患者的存活率.
研究的目的:
- 研究瘤相关巨细胞 (TAM) 在ImmTAC治疗疗效中的作用.
- 确定TAM是否影响tebentafusp在mUM中的抗瘤活性.
- 探索克服TAM介导抑制的策略.
主要方法:
- 使用M2巨细胞和T细胞进行体外研究.
- 在2期试验的患者样本中分析TAM-to-T细胞比率.
- 对ImmTAC和IL-2的反应中巨细胞重编程 (M2到M1) 的评估.
主要成果:
- 在体外,M2巨细胞抑制了ImmTAC介导的瘤杀伤.
- 高基线内TAM-T细胞比率与tebentafusp治疗患者的总生存时间 (OS) 较短相关.
- T细胞的IL-2调节克服了M2巨细胞的抑制;tebentafusp诱导了M2到M1巨细胞的重编程.
结论:
- 泰班塔法斯普重塑瘤的微环境,以提高抗瘤T细胞的活性.
- 将tebentafusp与IL-2结合使用可能会增强高TAM水平的mUM患者的治疗效益.
- 向TAM可能是改善阴道黑色素瘤治疗结果的策略.
相关概念视频
01:27Tumor Immunotherapy
457
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
457
02:17The Tumor Microenvironment
6.5K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.5K